vs
Allegiant Travel CO（ALGT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Allegiant Travel CO的1.1倍（$772.1M vs $732.4M），Revvity净利率更高（12.7% vs 5.8%，领先6.9%），Revvity同比增速更快（5.9% vs 4.8%），过去两年Allegiant Travel CO的营收复合增速更高（11.0% vs 9.0%）
忠实航空是美国的一家低成本航空公司，总部位于内华达州拉斯维加斯。该航司主打超低成本运营模式，基础票价包含服务极少，通过大量附加服务收取额外费用，核心服务对象是中小城市尚未被充分覆盖的休闲出行客流。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ALGT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$732.4M
营收增速更快
RVTY
高出1.1%
4.8%
净利率更高
RVTY
高出6.9%
5.8%
两年增速更快
ALGT
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $732.4M | $772.1M |
| 净利润 | $42.5M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 11.1% | 14.5% |
| 净利率 | 5.8% | 12.7% |
| 营收同比 | 4.8% | 5.9% |
| 净利润同比 | 32.4% | 3.9% |
| 每股收益（稀释后） | $2.30 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGTRVTY
| Q1 26 | $732.4M | — | ||
| Q4 25 | $595.5M | $772.1M | ||
| Q3 25 | $494.1M | $698.9M | ||
| Q2 25 | $617.9M | $720.3M | ||
| Q1 25 | $616.8M | $664.8M | ||
| Q4 24 | $553.6M | $729.4M | ||
| Q3 24 | $489.0M | $684.0M | ||
| Q2 24 | $594.5M | $691.7M |
净利润ALGTRVTY
| Q1 26 | $42.5M | — | ||
| Q4 25 | $31.9M | $98.4M | ||
| Q3 25 | $-43.6M | $46.7M | ||
| Q2 25 | $-65.2M | $53.9M | ||
| Q1 25 | $32.1M | $42.2M | ||
| Q4 24 | $-216.2M | $94.6M | ||
| Q3 24 | $-36.8M | $94.4M | ||
| Q2 24 | $13.7M | $55.4M |
毛利率ALGTRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率ALGTRVTY
| Q1 26 | 11.1% | — | ||
| Q4 25 | 11.2% | 14.5% | ||
| Q3 25 | -5.5% | 11.7% | ||
| Q2 25 | -10.9% | 12.6% | ||
| Q1 25 | 10.5% | 10.9% | ||
| Q4 24 | -47.7% | 16.3% | ||
| Q3 24 | -5.4% | 14.3% | ||
| Q2 24 | 5.9% | 12.4% |
净利率ALGTRVTY
| Q1 26 | 5.8% | — | ||
| Q4 25 | 5.4% | 12.7% | ||
| Q3 25 | -8.8% | 6.7% | ||
| Q2 25 | -10.5% | 7.5% | ||
| Q1 25 | 5.2% | 6.4% | ||
| Q4 24 | -39.1% | 13.0% | ||
| Q3 24 | -7.5% | 13.8% | ||
| Q2 24 | 2.3% | 8.0% |
每股收益（稀释后）ALGTRVTY
| Q1 26 | $2.30 | — | ||
| Q4 25 | $1.82 | $0.86 | ||
| Q3 25 | $-2.41 | $0.40 | ||
| Q2 25 | $-3.62 | $0.46 | ||
| Q1 25 | $1.73 | $0.35 | ||
| Q4 24 | $-12.12 | $0.77 | ||
| Q3 24 | $-2.05 | $0.77 | ||
| Q2 24 | $0.75 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $902.1M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | — | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALGTRVTY
| Q1 26 | $902.1M | — | ||
| Q4 25 | $805.7M | $919.9M | ||
| Q3 25 | $956.7M | $931.4M | ||
| Q2 25 | $842.8M | $991.8M | ||
| Q1 25 | $878.6M | $1.1B | ||
| Q4 24 | $781.1M | $1.2B | ||
| Q3 24 | $759.3M | $1.2B | ||
| Q2 24 | $791.9M | $2.0B |
总债务ALGTRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.8B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.7B | — |
股东权益ALGTRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $7.3B | ||
| Q3 25 | $1.0B | $7.4B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.3B | $7.9B | ||
| Q2 24 | $1.3B | $7.9B |
总资产ALGTRVTY
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | $12.2B | ||
| Q3 25 | $4.4B | $12.1B | ||
| Q2 25 | $4.4B | $12.4B | ||
| Q1 25 | $4.5B | $12.4B | ||
| Q4 24 | $4.4B | $12.4B | ||
| Q3 24 | $4.8B | $12.8B | ||
| Q2 24 | $4.9B | $13.4B |
负债/权益比ALGTRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.60× | — | ||
| Q3 25 | 1.76× | — | ||
| Q2 25 | 1.68× | — | ||
| Q1 25 | 1.57× | — | ||
| Q4 24 | 1.48× | — | ||
| Q3 24 | 1.36× | — | ||
| Q2 24 | 1.30× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ALGTRVTY
| Q1 26 | — | — | ||
| Q4 25 | $112.2M | $182.0M | ||
| Q3 25 | $-6.1M | $138.5M | ||
| Q2 25 | $92.2M | $134.3M | ||
| Q1 25 | $191.4M | $128.2M | ||
| Q4 24 | $84.4M | $174.2M | ||
| Q3 24 | $17.3M | $147.9M | ||
| Q2 24 | $68.9M | $158.6M |
自由现金流ALGTRVTY
| Q1 26 | — | — | ||
| Q4 25 | $90.4M | $161.8M | ||
| Q3 25 | $-121.7M | $120.0M | ||
| Q2 25 | $-10.5M | $115.5M | ||
| Q1 25 | $116.9M | $112.2M | ||
| Q4 24 | $24.0M | $149.8M | ||
| Q3 24 | $-28.7M | $125.6M | ||
| Q2 24 | $7.0M | $136.6M |
自由现金流率ALGTRVTY
| Q1 26 | — | — | ||
| Q4 25 | 15.2% | 21.0% | ||
| Q3 25 | -24.6% | 17.2% | ||
| Q2 25 | -1.7% | 16.0% | ||
| Q1 25 | 19.0% | 16.9% | ||
| Q4 24 | 4.3% | 20.5% | ||
| Q3 24 | -5.9% | 18.4% | ||
| Q2 24 | 1.2% | 19.7% |
资本支出强度ALGTRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.7% | 2.6% | ||
| Q3 25 | 23.4% | 2.6% | ||
| Q2 25 | 16.6% | 2.6% | ||
| Q1 25 | 12.1% | 2.4% | ||
| Q4 24 | 10.9% | 3.4% | ||
| Q3 24 | 9.4% | 3.3% | ||
| Q2 24 | 10.4% | 3.2% |
现金转化率ALGTRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.51× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 5.96× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 5.03× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALGT
| Passenger | $671.8M | 92% |
| Third party products | $42.3M | 6% |
| Fixed fee contracts | $18.1M | 2% |
| Resort and other | $175.0K | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
